南微医学
(688029)
| 流通市值：130.87亿 | | | 总市值：130.87亿 |
| 流通股本：1.88亿 | | | 总股本：1.88亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,012,446,160.41 | 1,333,844,008.46 | 620,078,643.58 | 2,411,468,385.36 |
| 营业收入 | 2,012,446,160.41 | 1,333,844,008.46 | 620,078,643.58 | 2,411,468,385.36 |
| 二、营业总成本 | 1,467,685,015.45 | 958,202,375.17 | 447,485,577.57 | 1,854,314,053.6 |
| 营业成本 | 651,175,548.98 | 427,674,897.51 | 196,484,985.91 | 855,981,926.49 |
| 税金及附加 | 23,328,191.94 | 15,513,738.19 | 6,128,792.57 | 24,094,398.56 |
| 销售费用 | 465,159,798.73 | 303,232,123.84 | 134,457,580.03 | 572,528,707.7 |
| 管理费用 | 249,161,760.14 | 165,850,464.83 | 82,485,457.06 | 328,738,169.12 |
| 研发费用 | 111,568,259.5 | 69,580,698.86 | 30,920,136.25 | 150,803,264.76 |
| 财务费用 | -32,708,543.84 | -23,649,548.06 | -2,991,374.25 | -77,832,413.03 |
| 其中:利息费用 | 2,016,604.94 | 1,704,427.12 | 760,922.45 | 2,041,048.83 |
| 其中:利息收入 | 52,756,958.52 | 36,200,403.22 | 15,689,602.29 | 49,927,116.29 |
| 加:公允价值变动收益 | -6,431.02 | -145,593.34 | 1,276,235.99 | 15,881.06 |
| 加:投资收益 | 15,371,554.09 | 10,997,694.12 | 2,803,690.3 | 27,824,812.68 |
| 资产处置收益 | 7,295.87 | 7,295.87 | - | 60,473.02 |
| 资产减值损失(新) | -18,458,996.41 | -12,511,305.14 | -4,246,855.29 | -34,641,137.34 |
| 信用减值损失(新) | -5,049,438.24 | -4,788,715.71 | -873,401.52 | -1,056,116.53 |
| 其他收益 | 3,456,377.66 | 2,477,697.95 | 1,406,290.65 | 5,310,900.83 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 540,081,506.91 | 371,678,707.04 | 172,959,026.14 | 554,669,145.48 |
| 加:营业外收入 | 2,402,579.67 | 1,506,204.42 | 768,275.76 | 17,183,039.51 |
| 减:营业外支出 | 237,479.97 | 89,819.83 | 18,781.12 | 6,942,267.37 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 542,246,606.61 | 373,095,091.63 | 173,708,520.78 | 564,909,917.62 |
| 减:所得税费用 | 78,213,733.65 | 53,096,345.54 | 26,253,742.04 | 70,209,366.1 |
| 六、净利润 | 464,032,872.96 | 319,998,746.09 | 147,454,778.74 | 494,700,551.52 |
| 持续经营净利润 | 464,032,872.96 | 319,998,746.09 | 147,454,778.74 | 494,700,551.52 |
| 归属于母公司股东的净利润 | 451,093,598.62 | 310,462,903.96 | 143,464,442.08 | 485,924,270.19 |
| 少数股东损益 | 12,939,274.34 | 9,535,842.13 | 3,990,336.66 | 8,776,281.33 |
| (一)基本每股收益 | 2.41 | 1.66 | 0.76 | 2.59 |
| (二)稀释每股收益 | 2.41 | 1.66 | 0.76 | 2.59 |
| 八、其他综合收益 | -1,088,120.39 | -2,329,147.63 | -4,059,448.59 | 2,085,032.26 |
| 归属于母公司股东的其他综合收益 | -1,089,950.81 | -2,328,097.77 | -4,059,158.44 | 2,087,736.51 |
| 九、综合收益总额 | 462,944,752.57 | 317,669,598.46 | 143,395,330.15 | 496,785,583.78 |
| 归属于母公司股东的综合收益总额 | 450,003,647.81 | 308,134,806.19 | 139,405,283.64 | 488,012,006.7 |
| 归属于少数股东的综合收益总额 | 12,941,104.76 | 9,534,792.27 | 3,990,046.51 | 8,773,577.08 |
| 公告日期 | 2024-10-30 | 2024-08-23 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |